年轻人与老年人的高血压归因性中风负担:对GBD 2021和NHANES数据库的分析
Fanqi Li1, Jiasong Li2, Siyuan Tan1
1Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha 410000, China.
American journal of preventive cardiology
|November 24, 2025
概括
高血压显著导致全球中风死亡. 年轻人面临较慢的死亡率下降,较差的高血压管理和更大的健康差异,需要有针对性的干预措施.
科学领域:
- 心血管流行病学心血管流行病学
- 公共卫生 公共卫生
- 老年学是一门学科.
背景情况:
- 高血压是全球中风的主要驱动因素,是死亡的主要原因.
- 心血管疾病,包括中风,正在越来越多地影响年轻人群.
- 这项研究调查了年轻和年长的成年人年龄组中高血压归因于中风的差异性负担.
研究的目的:
- 为了比较高血压对中风死亡率和控制在年轻人 (25-54岁) 与老年人 (≥55岁) 成人的影响.
- 根据年龄组分析高血压相关中风死亡率降低率的趋势.
- 为了评估高血压意识,控制和健康不平等的差异在不同年龄的人口统计学.
主要方法:
- 利用了全球疾病负担 (GBD) 和美国国家健康和营养检查调查 (NHANES) 数据库.
- 应用年龄-周期-队列 (APC) 建模来分析中风死亡率趋势和估计年度百分比变化 (EAPC).
- 计算了健康不平等的度指数,并评估了NHANES参与者的高血压意识和控制率.
主要成果:
- 高血压占全球中风死亡人数的50.5%.
- 与老年人 (≥55岁) 相比,由于高血压而导致的中风的死亡率降低率在年轻人 (25-54岁) 中较慢.
- 年轻的高血压成年人表现出更高的失控高血压和不意识率,健康不平等的增加集中在社会经济地位较低的国家,在年轻人群中更为明显.
结论:
- 高血压仍然是中风的关键风险因素,不成比例地影响年轻人群.
- 年轻的成年人在中风死亡率下降,高血压管理的恶化和健康不平等的扩大方面经历了不太有利的趋势.
- 针对年龄的公共卫生策略和干预措施对于应对年轻人口中与高血压相关的中风日益增加的负担至关重要.
更多相关视频
05:51Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness
Published on: May 3, 2018
18.3K
09:11Performing Permanent Distal Middle Cerebral with Common Carotid Artery Occlusion in Aged Rats to Study Cortical Ischemia with Sustained Disability
Published on: February 23, 2016
22.9K
相关概念视频
01:28Hypertension I: Introduction
720
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
720
01:29Hypertension II: Pathophysiology
763
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
763
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
451
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
451
01:18Hypertension and Regulation of Blood Pressure
3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
595
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
595
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180